相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2021)
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Aurelie Kamoun et al.
EUROPEAN UROLOGY (2020)
A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera
Sherwin Jack et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer
Vasty Osei-Amponsa et al.
ONCOGENE (2020)
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Andrea Necchi et al.
EUROPEAN UROLOGY (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.
David I. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results
Sumanta K. Pal et al.
CANCER (2020)
Erdafitinib for the treatment of metastatic bladder cancer
Kamaneh Montazeri et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.
Arlene O. Siefker-Radtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.
Victor Moreno et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
Andrea B. Apolo et al.
LANCET ONCOLOGY (2020)
Prevention and treatment of FGFR inhibitor-associated toxicities
Amit Mahipal et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
Nazli Dizman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Management of Urothelial Bladder Cancer in Clinical Practice: Real-world Answers to Difficult Questions
Nataliya Mar et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
902OAn adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
T Powles et al.
ANNALS OF ONCOLOGY (2019)
Ibrutinib in CLL/SLL: From bench to bedside
Fuming Zi et al.
ONCOLOGY REPORTS (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Bergerot et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Novel therapies in urothelial carcinoma: a biomarker-driven approach
G. Iyer et al.
ANNALS OF ONCOLOGY (2018)
Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1-3 who failed on platinum-based chemotherapy (CT).
Albert Font Pous et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
Ji Yun Lee et al.
TRANSLATIONAL ONCOLOGY (2018)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Sumanta K. Pal et al.
CANCER DISCOVERY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
Pedro Miguel Lacal et al.
PHARMACOLOGICAL RESEARCH (2018)
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2018)
Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis
Koji Yamasaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Paolo M. Comoglio et al.
NATURE REVIEWS CANCER (2018)
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Noah M. Hahn et al.
CLINICAL CANCER RESEARCH (2017)
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma
Liqin Wang et al.
EUROPEAN UROLOGY (2017)
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer
Robert J. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
Pontus Eriksson et al.
ONCOTARGET (2017)
Bladder cancer
Oner Sanli et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
Tumor endothelial cells accelerate tumor metastasis
Nako Maishi et al.
CANCER SCIENCE (2017)
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
J. Molina-Cerrillo et al.
CANCER TREATMENT REVIEWS (2017)
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia
Emma D. Deeks
DRUGS (2017)
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Kurt Miller et al.
UROLOGIA INTERNATIONALIS (2016)
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Andrew J. Gunderson et al.
CANCER DISCOVERY (2016)
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity
Frank E. Kwarcinski et al.
ACS CHEMICAL BIOLOGY (2016)
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront et al.
BJU INTERNATIONAL (2016)
Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy
Tetsutaro Hayashi et al.
CLINICAL CANCER RESEARCH (2016)
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
Sujata Narayanan et al.
CLINICAL GENITOURINARY CANCER (2016)
A place for precision medicine in bladder cancer: targeting the FGFRs
Erica Di Martino et al.
FUTURE ONCOLOGY (2016)
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
Noura J. Choudhury et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Therapeutics Targeting FGF Signaling Network in Human Diseases
Masaru Katoh
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Vivek Narayan et al.
CANCER RESEARCH AND TREATMENT (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bladder Preservation for Muscle Invasive Bladder Cancer
Arafat Mirza et al.
BLADDER CANCER (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten et al.
CANCER AND METASTASIS REVIEWS (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
HACE1 mediated K27 ubiquitin linkage leads to YB-1 protein secretion
Vivek Reddy Palicharla et al.
CELLULAR SIGNALLING (2015)
Multicentre randomised phase II trial of gemcitabine plus platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stephane Oudard et al.
EUROPEAN JOURNAL OF CANCER (2015)
SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
Thomas Geldart et al.
EUROPEAN UROLOGY (2015)
NOTCH pathway inactivation promotes bladder cancer progression
Antonio Maraver et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Phase 2 study of the pan-isoform PI3 kinase inhibitor BKM120 in metastatic urothelial carcinoma patients.
Gopa Iyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Complexity of FGFR signalling in metastatic urothelial cancer
Alejo Rodriguez-Vida et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence
Benjamin A. Mooso et al.
JOURNAL OF UROLOGY (2015)
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)
Guenter Niegisch et al.
ONCOLOGY (2015)
PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
Pengda Liu et al.
CANCER DISCOVERY (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
NOTCH Decoys That Selectively Block DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth
Thaned Kangsamaksin et al.
CANCER DISCOVERY (2015)
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2014)
Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
N. Cihoric et al.
BRITISH JOURNAL OF CANCER (2014)
Double-Blind, Randomized, Phase 2 Trial of Maintenance Sunitinib Versus Placebo After Response to Chemotherapy in Patients With Advanced Urothelial Carcinoma
Petros D. Grivas et al.
CANCER (2014)
A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma
Maha Hussain et al.
CANCER (2014)
A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
Jeffrey S. Ross et al.
CLINICAL CANCER RESEARCH (2014)
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I. Milowsky et al.
EUROPEAN JOURNAL OF CANCER (2014)
Tumor infiltrating B-cells are increased in prostate cancer tissue
Jason R. Woo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Identification of ALK Gene Alterations in Urothelial Carcinoma
Joaquim Bellmunt et al.
PLOS ONE (2014)
Reduced membranous MET expression is linked to bladder cancer progression
Martina Kluth et al.
CANCER GENETICS (2014)
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
Holger Gerullis et al.
ANTI-CANCER DRUGS (2013)
Phase II study of everolimus in metastatic urothelial cancer
Matthew I. Milowsky et al.
BJU INTERNATIONAL (2013)
A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
Roberto Pili et al.
CLINICAL GENITOURINARY CANCER (2013)
The Down-Regulation of Notch1 Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Inactivating the Cyclooxygenase-2/Snail/E-cadherin Pathway In Vitro
Liang Zhou et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
Arjun V. Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
V. Chell et al.
ONCOGENE (2013)
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
E. Seront et al.
ANNALS OF ONCOLOGY (2012)
Mutations increased overexpression of Notch1 in T-cell acute lymphoblastic leukemia
Chunlan Lin et al.
CANCER CELL INTERNATIONAL (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
Yu-Ning Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center
Arlene O. Siefker-Radtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
Laurent Arnouldi et al.
MODERN PATHOLOGY (2012)
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Andrea Necchi et al.
LANCET ONCOLOGY (2012)
Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma
Yasuko Hanabata et al.
ODONTOLOGY (2012)
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL
A. E. Sayan et al.
ONCOGENE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
ALK signaling and target therapy in anaplastic large cell lymphoma
Fabrizio Tabbo et al.
FRONTIERS IN ONCOLOGY (2012)
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2011)
Germline Gain-of-Function Mutations of ALK Disrupt Central Nervous System Development
Loic de Pontual et al.
HUMAN MUTATION (2011)
Molecular control of endothelial cell behaviour during blood vessel morphogenesis
Shane P. Herbert et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
Daniel P. Petrylak et al.
BJU INTERNATIONAL (2010)
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity
Hu Zhu et al.
CANCER LETTERS (2010)
Cross-talk between miRNA and Notch signaling pathways in tumor development and progression
Zhiwei Wang et al.
CANCER LETTERS (2010)
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus
Longfei Huo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
Przemyslaw Twardowski et al.
UROLOGY (2010)
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102
G. K. Philips et al.
ANNALS OF ONCOLOGY (2009)
A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
Christian Wuelfing et al.
CANCER (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Raphael Kopan et al.
CELL (2009)
Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker
Geraldine Pignot et al.
EUROPEAN UROLOGY (2009)
The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - the prognostic contribution of related molecular markers
Julieta Afonso et al.
HISTOPATHOLOGY (2009)
Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and-7 and E-cadherin
Yasuyoshi Miyata et al.
HUMAN PATHOLOGY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Induction of ERBB2 Nuclear Transport after Radiation in Breast Cancer Cells
Bo Luo et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2009)
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
Chih-Chen Hong et al.
CANCER LETTERS (2008)
Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression
Liang-Yi Hung et al.
NUCLEIC ACIDS RESEARCH (2008)
The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus
Jayoung Kim et al.
CANCER RESEARCH (2007)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tyrosine phosphorylation controls PCNA function through protein stability
Shao-Chun Wang et al.
NATURE CELL BIOLOGY (2006)
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival
HW Lo et al.
BRITISH JOURNAL OF CANCER (2006)
Notch signalling: a simple pathway becomes complex
Sarah J. Bray
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Multiple roles for the receptor tyrosine kinase Axl in tumor formation
SJ Holland et al.
CANCER RESEARCH (2005)
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer
K Macleod et al.
CANCER RESEARCH (2005)
Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma
KM Ericson et al.
BMC CANCER (2005)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
SC Wang et al.
CANCER CELL (2004)
Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer
VE Theodoropoulos et al.
EUROPEAN UROLOGY (2004)
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Jiyong Liang et al.
CELL CYCLE (2003)
Src in cancer: deregulation and consequences for cell behaviour
MC Frame
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2002)
Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer
S Bernardini et al.
JOURNAL OF UROLOGY (2001)
HIF-1: Using two hands to flip the angiogenic switch
GL Semenza
CANCER AND METASTASIS REVIEWS (2000)
A novel proteolytic cleavage involved in Notch signaling:: The role of the disintegrin-metalloprotease TACE
C Brou et al.
MOLECULAR CELL (2000)
分享论文
